Positive news flowed in at
Nymox Pharmaceutical Corporation
) recently when the Independent Data Monitoring Committee (IDMC)
reported the third positive analysis of safety data from the
company's ongoing phase II study (NX03-0040) of NX-1207 for low
grade localized prostate cancer.
The IDMC's interim safety analysis found no significant safety
concerns associated with the use of NX-1207 for the treatment of
low risk localized prostate cancer. The NX03-0040 study is
assessing the efficacy and safety of both low (2.5 mg) and high
(15 mg) single doses of NX-1207 in eradicating or shrinking low
grade localized prostate cancer tumors. The phase II study is
ongoing and is expected to be completed by May 2013.
NX-1207 is in phase III development both in the US and Europe for
the treatment of patients suffering from benign prostatic
hyperplasia (BPH). In Europe, the company has a licensing
agreement with Recordati S.p.A. Recordati is sponsoring the
recently initiated phase III study in Europe.
We note that the prostrate cancer market offers a lucrative
opportunity. Currently approved prostate cancer treatments
Johnson & Johnson
) Zytiga. Moreover, the prostate cancer market saw a new entrant
in Aug 2012 in the form of
) Xtandi (enzalutamide).
Nymox Pharma currently carries a Zacks Rank #3 (Hold). Stocks
that currently look attractive in the pharma space include
) carrying a Zacks Rank #1 (Strong Buy).
CYTOKINETCS INC (CYTK): Free Stock Analysis
JOHNSON & JOHNS (JNJ): Free Stock Analysis
MEDIVATION INC (MDVN): Free Stock Analysis
NYMOX PHARMACTL (NYMX): Free Stock Analysis
To read this article on Zacks.com click here.